International union of basic and clinical pharmacology. LXXXVI. Orexin receptor function, nomenclature and pharmacology

Pharmacological Reviews

Volumn 64, Issue 3, 2012, Pages 389-420

  Gotter, Anthony L ^a   Webber, Andrea L ^a   Coleman, Paul J ^a   Renger, John J ^a   Winrow Dr , Christopher J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; 1 (6,8 DIFLUORO 2 METHYL 4 QUINOLINYL) 3 (4 DIMETHYLAMINOPHENYL)UREA; 1 (6,8 DIFLUORO 2 METHYL QUINOLIN 4 YL) 3 (4 DIMETHYLAMINO PHENYL)UREA; 5 BROMO N [1 (3 FLUORO 2 METHOXYBENZOYL) 5 METHYLPIPERIDIN 2 YL]METHYL PYRIDIN 2 AMINE; 5 [[(5 FLUOROPYRIDIN 2 YL)OXY]METHYL] 2 METHYLPIPERIDIN 1 YL][5 METHYL 2 (PYRIMIDIN 2 YL)PHENYL]METHANONE; ALMOREXANT; CALCIUM ION; DORA 1; DORA 12; DORA 22; GSK 1059865; GUANINE NUCLEOTIDE BINDING PROTEIN; JNJ 10397049; MK 6096; N ETHYL 2 [(6 METHOXYPYRIDIN 3 YL)(TOLUENE 2 SULFONYL)AMINO] N PYRIDIN 3 YLMETHYL ACETAMIDE; NEUROPEPTIDE FF RECEPTOR 2; NEUROPEPTIDE RECEPTOR; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; OREXIN RECEPTOR; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; SB 649868; SB 674042; SUVOREXANT; UNCLASSIFIED DRUG; ZOLPIDEM; [1 (2,4 DIBROMOPHENYL) 3 [2,2 DIMETHYL 4 PHENYL 1,3 DIOXAN 5 YL]UREA;

ADDICTION; ALERTNESS; ANXIETY; AROUSAL; ARTICLE; ATTENTION DISTURBANCE; CARDIOVASCULAR FUNCTION; CATAPLEXY; COGNITION; DEPRESSION; DIZZINESS; DRUG HALF LIFE; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; FATIGUE; GENE PRODUCT; GENETIC CONSERVATION; GENETIC MANIPULATION; HUMAN; HYPERSOMNIA; INSOMNIA; NARCOLEPSY; NERVE CELL; NERVE CELL EXCITABILITY; NOCICEPTION; NOMENCLATURE; NONHUMAN; NONREM SLEEP; OREXINERGIC NERVE CELL; PLASMA HALF LIFE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; REM SLEEP; REWARD; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; SLEEP; SLEEP DEPRIVATION; SLEEP DISORDER; SLEEP STAGE; SLEEP WAKING CYCLE; SOMNOLENCE; WAKEFULNESS;

EID: 84930481666     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.111.005546     Document Type: Article

References (321)

1. Adamantidis AR, Zhang F, Aravanis AM, Deisseroth K, and de Lecea L (2007) Neural substrates of awakening probed with optogenetic control of hypocretin neurons. Nature 450:420-424
2. Akanmu MA and Honda K (2005) Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats. Brain Res 1048:138-145
3. Alvaro G, Amantini D, and Belvedere S (2009), inventors; GlaxoSmithKline, Alvaro G, Amantini D, and Belvedere S, assignees. Novel compounds. U.S. patent application no. 2009022670. 2009 Jan 22
4. Alvaro G, Amantini D, and Stasi LP (2011), inventors; GlaxoSmithKline, Alvaro G, Amantini D, and Stasi LP, assignees. Pyridine derivatives used to treat orexin related disorders. U.S. patent application no. 20110053979. 2011 Mar 3
5. Antunes VR, Brailoiu GC, Kwok EH, Scruggs P, and Dun NJ (2001) Orexins/hypocretins excite rat sympathetic preganglionic neurons in vivo and in vitro. Am J Physiol Regul Integr Comp Physiol 281:R1801-R1807
6. Arrigoni E, Mochizuki T, and Scammell TE (2010) Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol (Oxf) 198:223-235
7. Asahi S, Egashira S, Matsuda M, Iwaasa H, Kanatani A, Ohkubo M, Ihara M, and Morishima H (2003) Development of an orexin-2 receptor selective agonist, [Ala(11), D-Leu(15)]orexin-B. Bioorg Med Chem Lett 13:111-113
8. Ashton H (1994) Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 48:25-40
9. Aston-Jones G, Smith RJ, Sartor GC, Moorman DE, Massi L, Tahsili-Fahadan P, and Richardson KA (2010) Lateral hypothalamic orexin/hypocretin neurons: A role in reward-seeking and addiction. Brain Res 1314:74-90
10. Avolio E, Alò R, Carelli A, and Canonaco M (2011) Amygdalar orexinergic-GABAergic interactions regulate anxiety behaviors of the Syrian golden hamster. Behav Brain Res 218:288-295
11. Baccari BC (2010) Orexins and gastrointestinal functions. Curr Protein Pept Sci 11:148-155
12. Bartsch T, Levy MJ, Knight YE, and Goadsby PJ (2004) Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain 109:367-378
13. Bastianini S, Silvani A, Berteotti C, Elghozi JL, Franzini C, Lenzi P, Lo Martire V, and Zoccoli G (2011) Sleep related changes in blood pressure in hypocretin-deficient narcoleptic mice. Sleep 34:213-218
14. Beck B and Richy S (1999) Hypothalamic hypocretin/orexin and neuropeptide Y: divergent interaction with energy depletion and leptin. Biochem Biophys Res Commun 258:119-122
15. Bengtsson MW, Mäkelä K, Herzig KH, and Flemström G (2009) Short food deprivation inhibits orexin receptor 1 expression and orexin-A induced intracellular calcium signaling in acutely isolated duodenal enterocytes. Am J Physiol Gastrointest Liver Physiol 296:G651-G658
16. Bengtsson MW, Mäkelä K, Sjöblom M, Uotila S, Akerman KE, Herzig KH, and Flemström G (2007) Food-induced expression of orexin receptors in rat duodenal mucosa regulates the bicarbonate secretory response to orexin-A. Am J Physiol Gastrointest Liver Physiol 293:G501-G509
17. Bergman JM, Roecker AJ, Mercer SP, Bednar RA, Reiss DR, Ransom RW, Meacham Harrell C, Pettibone DJ, Lemaire W, Murphy KL, et al. (2008) Proline bis-amides as potent dual orexin receptor antagonists. Bioorg Med Chem Lett 18:1425-1430
18. Bernardis LL and Bellinger LL (1996) The lateral hypothalamic area revisited: ingestive behavior. Neurosci Biobehav Rev 20:189-287
19. Bernardis LL, Ciesla A, and Bellinger LL (1993) Hypophagic rats with dorsomedial hypothalamic lesions produce lighter and smaller pups with a lower survival rate at weaning than offspring of sham-operated controls. Physiol Behav 53:59-64
20. Berridge CW, España RA, and Vittoz NM (2010) Hypocretin/orexin in arousal and stress. Brain Res 1314:91-102
21. Bettica P, Nucci G, Pyke C, Squassante L, Zamuner S, Ratti E, Gomeni R and Alexander R (2011) Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist. J Psychopharmacol http://dx.doi.org/10.1177/0269881111408954
22. Bettica PU, Lichtenfeld U, Squassante L, Shabbir S, Zuechner D, Dreykluft P, Lehmann R, Danker-Hopfe H, and Ratti E (2009) The orexin antagonist SB-649868 promotes and maintains sleep in healthy volunteers and in patients with primary insomnia (Abstract 0774). Sleep 32 (Suppl):A252-A253
23. Bettica P, Squassante L, Groeger JA, Gennery B, Winsky-Sommerer R, and Dijk DJ (2012) Differential effects of a dual orexin receptor antagonist (SB-649868) and zolpidem on sleep initiation and consolidation, SWS, REM sleep, and EEG power spectra in a model of situational insomnia. Neuropsychopharmacology 37:1224-1233
24. Beuckmann CT, Sinton CM, Williams SC, Richardson JA, Hammer RE, Sakurai T, and Yanagisawa M (2004) Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J Neurosci 24:4469-4477
25. Beuckmann CT and Yanagisawa M (2002) Orexins: from neuropeptides to energy homeostasis and sleep/wake regulation. J Mol Med (Berl) 80:329-342
26. Bingham S, Davey PT, Babbs AJ, Irving EA, Sammons MJ, Wyles M, Jeffrey P, Cutler L, Riba I, Johns A, et al. (2001) Orexin-A, an hypothalamic peptide with analgesic properties. Pain 92:81-90
27. Borgland SL, Storm E, and Bonci A (2008) Orexin B/hypocretin 2 increases glutamatergic transmission to ventral tegmental area neurons. Eur J Neurosci 28: 1545-1556
28. Borgland SL, Taha SA, Sarti F, Fields HL, and Bonci A (2006) Orexin A in the VTA is critical for the induction of synaptic plasticity and behavioral sensitization to cocaine. Neuron 49:589-601
29. Bourgin P, Huitrón-Résendiz S, Spier AD, Fabre V, Morte B, Criado JR, Sutcliffe JG, Henriksen SJ, and de Lecea L (2000) Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J Neurosci 20:7760-7765
30. Boutrel B, Kenny PJ, Specio SE, Martin-Fardon R, Markou A, Koob GF, and de Lecea L (2005) Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci USA 102:19168-19173
31. Brisbare-Roch C, Clozel M, and Jenck F (2008) Effects of repeated oral administration of the orexin receptor antagonist almorexant in male rats and dogs. Sleep 31:A38
32. Brisbare-Roch C, Dingemanse J, Koberstein R, Hoever P, Aissaoui H, Flores S, Mueller C, Nayler O, van Gerven J, de Haas SL, et al. (2007) Promotion of sleep by targeting the orexin system in rats, dogs and humans. Nat Med 13:150-155
33. Brundin L, Björkqvist M, Petersén A, and Träskman-Bendz L (2007) Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol 17:573-579
34. Bülbül M, Babygirija R, Ludwig K, and Takahashi T (2010a) Central orexin-A increases gastric motility in rats. Peptides 31:2118-2122
35. Bülbül M, Tan R, Gemici B, Ozdem S, Ustünel I, Acar N, and Izgüt-Uysal VN (2010b) Endogenous orexin-A modulates gastric motility by peripheral mechanisms in rats. Peptides 31:1099-1108
36. Burdakov D and Alexopoulos H (2005) Metabolic state signalling through central hypocretin/orexin neurons. J Cell Mol Med 9:795-803
37. Burdakov D (2004) Electrical signaling in central orexin/hypocretin circuits: tuning arousal and appetite to fit the environment. Neuroscientist 10:286-291
38. Burgess CR, Tse G, Gillis L, and Peever JH (2010) Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 33:1295-1304
39. Carter ME, Adamantidis A, Ohtsu H, Deisseroth K, and de Lecea L (2009) Sleep homeostasis modulates hypocretin-mediated sleep-to-wake transitions. J Neurosci 29:10939-10949
40. Cason AM, Smith RJ, Tahsili-Fahadan P, Moorman DE, Sartor GC, and Aston-Jones G (2010) Role of orexin/hypocretin in reward-seeking and addiction: implications for obesity. Physiol Behav 100:419-428
41. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y, et al. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98:437-451
42. Chen CT, Hwang LL, Chang JK, and Dun NJ (2000) Pressor effects of orexins injected intracisternally and to rostral ventrolateral medulla of anesthetized rats. Am J Physiol Regul Integr Comp Physiol 278:R692-R697
43. Chen L, McKenna JT, Bolortuya Y, Winston S, Thakkar MM, Basheer R, Brown RE, and McCarley RW (2010) Knockdown of orexin type 1 receptor in rat locus coeruleus increases REM sleep during the dark period. Eur J Neurosci 32:1528-1536
44. Cheng JK, Chou RC, Hwang LL, and Chiou LC (2003) Antiallodynic effects of intrathecal orexins in a rat model of postoperative pain. J Pharmacol Exp Ther 307:1065-1071
45. Cherezov V, Rosenbaum DM, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Kuhn P, Weis WI, Kobilka BK, et al. (2007) High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 318:1258-1265
46. Choi DL, Davis JF, Fitzgerald ME, and Benoit SC (2010) The role of orexin-A in food motivation, reward-based feeding behavior and food-induced neuronal activation in rats. Neuroscience 167:11-20
47. Ciriello J and de Oliveira CV (2003) Cardiac effects of hypocretin-1 in nucleus ambiguus. Am J Physiol Regul Integr Comp Physiol 284:R1611-R1620
48. Ciriello J, Li Z, and de Oliveira CV (2003) Cardioacceleratory responses to hypocretin-1 injections into rostral ventromedial medulla. Brain Res 991:84-95
49. Clark EL, Baumann CR, Cano G, Scammell TE, and Mochizuki T (2009) Feedingelicited cataplexy in orexin knockout mice. Neuroscience 161:970-977
50. Coleman PJ, Cox CD, and Roecker AJ (2011a) Discovery of dual orexin receptor antagonists (DORAs) for the treatment of insomnia. Curr Top Med Chem 11:696-725
51. Coleman PJ and Renger JJ (2010) Orexin receptor antagonists: a review of promising compounds patented since 2006 Expert Opin Ther Pat 20:307-324
52. Coleman PJ, Schreier JD, Cox CD, Breslin MJ, Whitman DB, Bogusky MJ, Mc-Gaughey GB, Bednar RA, Lemaire W, Doran SM, et al. (2012) Discovery of [(2R,5R)-5-{[(5-fluoropyridin-2-yl)oxy]methyl}-2-methylpiperidin-1-yl][5-methyl-2-(pyrimidin-2-yl) phenyl] methanone (MK-6096): a dual orexin receptor antagonist with potent sleep-promoting properties. ChemMedChem 7:415-424
53. Costa E and Guidotti A (1979) Molecular mechanisms in the receptor action of benzodiazepines. Annu Rev Pharmacol Toxicol 19:531-545
54. Cox CD, Breslin MJ, Whitman DB, Schreier JD, McGaughey GB, Bogusky MJ, Roecker AJ, Mercer SP, Bednar RA, Lemaire W, et al. (2010) Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia. J Med Chem 53:5320-5332
55. Cox CD, McGaughey GB, Bogusky MJ, Whitman DB, Ball RG, Winrow CJ, Renger JJ, and Coleman PJ (2009) Conformational analysis of N,N-disubstituted-1,4-diazepane orexin receptor antagonists and implications for receptor binding. Bioorg Med Chem Lett 19:2997-3001
56. Dall'Aglio C, Pascucci L, Mercati F, Giontella A, Pedini V, and Ceccarelli P (2009) Immunohistochemical identification and localization of orexin A and orexin type 2 receptor in the horse gastrointestinal tract. Res Vet Sci 86:189-193
57. Dall'Aglio C, Pascucci L, Mercati F, Giontella A, Pedini V, Scocco P, and Ceccarelli P (2008) Identification of orexin A-and orexin type 2 receptor-positive cells in the gastrointestinal tract of neonatal dogs. Eur J Histochem 52:229-235
58. Dall'Aglio C, Pedini V, Scocco P, Boiti C, and Ceccarelli P (2010) Immunohistochemical evidence of Orexin-A in the pancreatic beta cells of domestic animals. Res Vet Sci 89:147-149
59. Date Y, Mondal MS, Matsukura S, and Nakazato M (2000) Distribution of orexin-A and orexin-B (hypocretins) in the rat spinal cord. Neurosci Lett 288:87-90
60. De la Herrán-Arita AK, Guerra-Crespo M, and Drucker-Colín R (2011) Narcolepsy and orexins: an example of progress in sleep research. Front Neurol 2:26.
61. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS 2nd, et al. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA 95:322-327.
62. de Oliveira CV, Rosas-Arellano MP, Solano-Flores LP, and Ciriello J (2003) Cardiovascular effects of hypocretin-1 in nucleus of the solitary tract. Am J Physiol Heart Circ Physiol 284:H1369-H1377
63. Deadwyler SA, Porrino L, Siegel JM, and Hampson RE (2007) Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 27:14239-14247
64. Deng BS, Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, and Kuwaki T (2007) Contribution of orexin in hypercapnic chemoreflex: evidence from genetic and pharmacological disruption and supplementation studies in mice. J Appl Physiol 103:1772-1779
65. Di Fabio R, Pellacani A, Faedo S, Roth A, Piccoli L, Gerrard P, Porter RA, Johnson CN, Thewlis K, Donati D, et al. (2011) Discovery process and pharmacological characterization of a novel dual orexin 1 and orexin 2 receptor antagonist useful for of sleep disorders. Bioorg Med Chem Lett 21:5562-5567
66. Dias MB, Li A, and Nattie E (2010) The orexin receptor 1 (OX1R) in the rostral medullary raphe contributes to the hypercapnic chemoreflex in wakefulness, during the active period of the diurnal cycle. Respir Physiol Neurobiol 170:96-102
67. Dias MB, Li A, and Nattie EE (2009) Antagonism of orexin receptor-1 in the retrotrapezoid nucleus inhibits the ventilatory response to hypercapnia predominantly in wakefulness. J Physiol 587:2059-2067
68. Dietrich H and Jenck F (2010) Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant. Psychopharmacology (Berl) 212:145-154
69. Dimitrova A, Fronczek R, Van der Ploeg J, Scammell T, Gautam S, Pascual-Leone A, and Lammers GJ (2011) Reward-seeking behavior in human narcolepsy. J Clin Sleep Med 7:293-300
70. Dingemanse J, Dorffner G, Hajak G, Benes H, Danker-Hopfe H, Polo O, Saletu B, Barbanoj MJ, Pillar G, Penzel T, et al. (2007) Proof-of-concept study in primary insomnia patients with ACT-078573, a dual orexin receptor antagonist (Abstract). Sleep Biol Rhythms 5 (Suppl):PO653 (A194).
71. Diniz Behn CG, Klerman EB, Mochizuki T, Lin SC, and Scammell TE (2010) Abnormal sleep/wake dynamics in orexin knockout mice. Sleep 33:297-306
72. Dube MG, Horvath TL, Kalra PS, and Kalra SP (2000) Evidence of NPY Y5 receptor involvement in food intake elicited by orexin A in sated rats. Peptides 21:1557-1560
73. Dugovic C, Shelton J, Sutton S, Yun S, Li X, Dvorak C, Carruthers N, Atack J, and Lovenberg T (2008) Sleep-inducing effects mediated by selective blockade of orexin OX2 receptors during the light phase in the rat (Abstract). Sleep 31:A33
74. Dugovic C, Shelton JE, Aluisio LE, Fraser IC, Jiang X, Sutton SW, Bonaventure P, Yun S, Li X, Lord B, et al. (2009) Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. J Pharmacol Exp Ther 330:142-151
75. Edwards CM, Abusnana S, Sunter D, Murphy KG, Ghatei MA, and Bloom SR (1999) The effect of the orexins on food intake: comparison with neuropeptide Y, melaninconcentrating hormone and galanin. J Endocrinol 160:R7-R12
76. Ehrström M, Gustafsson T, Finn A, Kirchgessner A, Grybäck P, Jacobsson H, Hellström PM, and Näslund E (2005a) Inhibitory effect of exogenous orexin a on gastric emptying, plasma leptin, and the distribution of orexin and orexin receptors in the gut and pancreas in man. J Clin Endocrinol Metab 90:2370-2377
77. Ehrström M, Levin F, Kirchgessner AL, Schmidt PT, Hilsted LM, Grybäck P, Jacobsson H, Hellström PM, and Näslund E (2005b) Stimulatory effect of endogenous orexin A on gastric emptying and acid secretion independent of gastrin. Regul Pept 132:9-16
78. Ehrström M, Näslund E, Ma J, Kirchgessner AL, and Hellström PM (2003) Physiological regulation and NO-dependent inhibition of migrating myoelectric complex in the rat small bowel by OXA. Am J Physiol Gastrointest Liver Physiol 285:G688-G695
79. Eriksson KS, Sergeeva OA, Selbach O, and Haas HL (2004) Orexin (hypocretin)/dynorphin neurons control GABAergic inputs to tuberomammillary neurons. Eur J Neurosci 19:1278-1284
80. España RA, McCormack SL, Mochizuki T, and Scammell TE (2007) Running promotes wakefulness and increases cataplexy in orexin knockout mice. Sleep 30: 1417-1425
81. España RA, Plahn S, and Berridge CW (2002) Circadian-dependent and circadianindependent behavioral actions of hypocretin/orexin. Brain Res 943:224-236
82. España RA and Scammell TE (2011) Sleep neurobiology from a clinical perspective. Sleep 34:845-858
83. Fadel J and Deutch AY (2002) Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neuroscience 111:379-387
84. Farr SA, Banks WA, Kumar VB, and Morley JE (2005) Orexin-A-induced feeding is dependent on nitric oxide. Peptides 26:759-765
85. Fenzl T, Romanowski CP, Flachskamm C, Deussing JM, and Kimura M (2011) Wake-promoting effects of orexin: Its independent actions against the background of an impaired corticotropine-releasing hormone receptor system. Behav Brain Res 222:43-50
86. Fortuyn HA, Lappenschaar MA, Furer JW, Hodiamont PP, Rijnders CA, Renier WO, Buitelaar JK, and Overeem S (2010) Anxiety and mood disorders in narcolepsy: a case-control study. Gen Hosp Psychiatry 32:49-56
87. Frederick-Duus D, Guyton MF, and Fadel J (2007) Food-elicited increases in cortical acetylcholine release require orexin transmission. Neuroscience 149:499-507
88. Fujiki N, Cheng T, Yoshino F, and Nishino S (2009) Specificity of direct transition from wake to REM sleep in orexin/ataxin-3 transgenic narcoleptic mice. Exp Neurol 217:46-54
89. Fujiki N, Yoshida Y, Ripley B, Honda K, Mignot E, and Nishino S (2001) Changes in CSF hypocretin-1 (orexin A) levels in rats across 24 hours and in response to food deprivation. Neuroreport 12:993-997
90. Fujiki N, Yoshida Y, Ripley B, Mignot E, and Nishino S (2003) Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin-ligand-deficient narcoleptic dog. Sleep 26:953-959
91. Funato H, Tsai AL, Willie JT, Kisanuki Y, Williams SC, Sakurai T, and Yanagisawa M (2009) Enhanced orexin receptor-2 signaling prevents diet-induced obesity and improves leptin sensitivity. Cell Metab 9:64-76
92. Furlong TM, Vianna DM, Liu L, and Carrive P (2009) Hypocretin/orexin contributes to the expression of some but not all forms of stress and arousal. Eur J Neurosci 30:1603-1614
93. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, Yanagisawa M, Nestler EJ, and DiLeone RJ (2003) Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 23:3106-3111
94. Gestreau C, Bévengut M, and Dutschmann M (2008) The dual role of the orexin/hypocretin system in modulating wakefulness and respiratory drive. Curr Opin Pulm Med 14:512-518
95. Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, Charney DS, and Krystal JH (2001) Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58:556-561
96. González JA, Jensen LT, Fugger L, and Burdakov D (2008) Metabolism-independent sugar sensing in central orexin neurons. Diabetes 57:2569-2576
97. Gozzi A, Turrini G, Piccoli L, Massagrande M, Amantini D, Antolini M, Martinelli P, Cesari N, Montanari D, Tessari M, et al. (2011) Functional magnetic resonance imaging reveals different neural substrates for the effects of orexin-1 and orexin-2 receptor antagonists. Plos One 6:e16406
98. Grabauskas G and Moises HC (2003) Gastrointestinal-projecting neurones in the dorsal motor nucleus of the vagus exhibit direct and viscerotopically organized sensitivity to orexin. J Physiol 549:37-56
99. Grudt TJ, van den Pol AN, and Perl ER (2002) Hypocretin-2 (orexin-B) modulation of superficial dorsal horn activity in rat. J Physiol 538:517-525
100. Hagan JJ, Leslie RA, Patel S, Evans ML, Wattam TA, Holmes S, Benham CD, Taylor SG, Routledge C, Hemmati P, et al. (1999) Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc Natl Acad Sci USA 96:10911-10916
101. Han F, Mignot E, Wei YC, Dong SX, Li J, Lin L, An P, Wang LH, Wang JS, He MZ, et al. (2010) Ventilatory chemoresponsiveness, narcolepsy-cataplexy and human leukocyte antigen DQB1*0602 status. Eur Respir J 36:577-583
102. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M, et al. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30:345-354
103. Hara J, Yanagisawa M, and Sakurai T (2005) Difference in obesity phenotype between orexin-knockout mice and orexin neuron-deficient mice with same genetic background and environmental conditions. Neurosci Lett 380:239-242
104. Harris GC and Aston-Jones G (2006) Arousal and reward: a dichotomy in orexin function. Trends Neurosci 29:571-577
105. Harris GC, Wimmer M, and Aston-Jones G (2005) A role for lateral hypothalamic orexin neurons in reward seeking. Nature 437:556-559
106. Haynes AC, Chapman H, Taylor C, Moore GB, Cawthorne MA, Tadayyon M, Clapham JC, and Arch JR (2002) Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 104:153-159
107. Haynes AC, Jackson B, Chapman H, Tadayyon M, Johns A, Porter RA, and Arch JR (2000) A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 96:45-51
108. Heinonen MV, Purhonen AK, Makela KA, and Herzig KH (2008) Functions of orexins in peripheral tissues. Acta Physiol (Oxf) 192:471-485
109. Herring WJ, Budd KS, Hutzelmann J, Snyder E, Snavely D, Liu K, Lines C, Michelson D, and Roth T (2010) Efficacy and tolerability of the dual orexin receptor antagonist mk-4305 in patients with primary insomnia: randomized, controlled, adaptive crossover polysomnography study (Abstract A0591). Sleep 33 (Suppl): A199
110. Hervieu GJ, Cluderay JE, Harrison DC, Roberts JC, and Leslie RA (2001) Gene expression and protein distribution of the orexin-1 receptor in the rat brain and spinal cord. Neuroscience 103:777-797
111. Hirota K, Kushikata T, Kudo M, Kudo T, Smart D, and Matsuki A (2003) Effects of central hypocretin-1 administration on hemodynamic responses in young-adult and middle-aged rats. Brain Res 981:143-150
112. Hoever P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J, and Dingemanse J (2010) Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant. Clin Pharmacol Ther 87:593-600
113. Holland PR, Akerman S, and Goadsby PJ (2005) Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 315:1380-1385
114. Holland PR, Akerman S, and Goadsby PJ (2006) Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 24:2825-2833
115. Holmqvist T, Akerman KE, and Kukkonen JP (2002) Orexin signaling in recombinant neuron-like cells. FEBS Lett 526:11-14
116. Honda Y, Doi Y, Ninomiya R, and Ninomiya C (1986) Increased frequency of noninsulin-dependent diabetes mellitus among narcoleptic patients. Sleep 9:254-259
117. Hoque R and Chesson AL, Jr. (2009) Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem. J Clin Sleep Med 5:471-476
118. Huang SC, Dai YW, Lee YH, Chiou LC, and Hwang LL (2010) Orexins depolarize rostral ventrolateral medulla neurons and increase arterial pressure and heart rate in rats mainly via orexin 2 receptors. J Pharmacol Exp Ther 334:522-529
119. Huang W, Ramsey KM, Marcheva B, and Bass J (2011) Circadian rhythms, sleep, and metabolism. J Clin Invest 121:2133-2141
120. Hungs M, Fan J, Lin L, Lin X, Maki RA, and Mignot E (2001) Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines. Genome Res 11:531-539
121. Ida T, Nakahara K, Katayama T, Murakami N, and Nakazato M (1999) Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res 821:526-529
122. Ida T, Nakahara K, Murakami T, Hanada R, Nakazato M, and Murakami N (2000) Possible involvement of orexin in the stress reaction in rats. Biochem Biophys Res Commun 270:318-323
123. Ishii Y, Blundell JE, Halford JC, Upton N, Porter R, Johns A, and Rodgers RJ (2004) Differential effects of the selective orexin-1 receptor antagonist SB-334867 and lithium chloride on the behavioural satiety sequence in rats. Physiol Behav 81: 129-140
124. Ishii Y, Blundell JE, Halford JC, Upton N, Porter R, Johns A, and Rodgers RJ (2005) Satiety enhancement by selective orexin-1 receptor antagonist SB-334867: influence of test context and profile comparison with CCK-8S. Behav Brain Res 160: 11-24
125. Ito N, Yabe T, Gamo Y, Nagai T, Oikawa T, Yamada H, and Hanawa T (2008) I.c.v. administration of orexin-A induces an antidepressive-like effect through hippocampal cell proliferation. Neuroscience 157:720-732
126. Jászberényi M, Bujdosó E, and Telegdy G (2001) The role of neuropeptide Y in orexin-induced hypothalamic-pituitary-adrenal activation. J Neuroendocrinol 13: 438-441
127. Jenck F, Fischer C, Qiu C, Hess P, Kolberstein R, and Brisbare-Roch C (2007) Somnolence induced by pharmacological blockade of both orexin OX1 and OX2 receptors in dogs (Abstract PO271). Sleep Biol Rhythms 5 (Suppl 1):A79
128. Jeong Y and Holden JE (2009) The role of spinal orexin-1 receptors in posterior hypothalamic modulation of neuropathic pain. Neuroscience 159:1414-1421
129. John J, Wu MF, Boehmer LN, and Siegel JM (2004) Cataplexy-active neurons in the hypothalamus: implications for the role of histamine in sleep and waking behavior. Neuron 42:619-634
130. Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, Träskman-Bendz L, Goddard AW, Brundin L, and Shekhar A (2010) A key role for orexin in panic anxiety. Nature Med 16:111-115
131. Kajiyama S, Kawamoto M, Shiraishi S, Gaus S, Matsunaga A, Suyama H, and Yuge O (2005) Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats. Brain Res 1044:76-86
132. Kalogiannis M, Grupke SL, Potter PE, Edwards JG, Chemelli RM, Kisanuki YY, Yanagisawa M, and Leonard CS (2010) Narcoleptic orexin receptor knockout mice express enhanced cholinergic properties in laterodorsal tegmental neurons. Eur J Neurosci 32:130-142
133. Kalogiannis M, Hsu E, Willie JT, Chemelli RM, Kisanuki YY, Yanagisawa M, and Leonard CS (2011) Cholinergic modulation of narcoleptic attacks in double orexin receptor knockout mice. PLoS ONE 6:e18697
134. Kantor S, Mochizuki T, Janisiewicz AM, Clark E, Nishino S, and Scammell TE (2009) Orexin neurons are necessary for the circadian control of REM sleep. Sleep 32:1127-1134
135. Karteris E, Machado RJ, Chen J, Zervou S, Hillhouse EW, and Randeva HS (2005) Food deprivation differentially modulates orexin receptor expression and signaling in rat hypothalamus and adrenal cortex. Am J Physiol Endocrinol Metab 288: E1089-E1100
136. Karteris E, Randeva HS, Grammatopoulos DK, Jaffe RB, and Hillhouse EW (2001) Expression and coupling characteristics of the CRH and orexin type 2 receptors in human fetal adrenals. J Clin Endocrinol Metab 86:4512-4519
137. Kastin AJ and Akerstrom V (1999) Orexin A but not orexin B rapidly enters brain from blood by simple diffusion. J Pharmacol Exp Ther 289:219-223
138. Katayama Y, Homma T, Honda K, and Hirai K (2003) Actions of orexin-A in the myenteric plexus of the guinea-pig small intestine. Neuroreport 14:1515-1518
139. Kayaba Y, Nakamura A, Kasuya Y, Ohuchi T, Yanagisawa M, Komuro I, Fukuda Y, and Kuwaki T (2003) Attenuated defense response and low basal blood pressure in orexin knockout mice. Am J Physiol Regul Integr Comp Physiol 285:R581-R593
140. Kirchgessner AL (2002) Orexins in the brain-gut axis. Endocr Rev 23:1-15
141. Kirchgessner AL and Liu M (1999) Orexin synthesis and response in the gut. Neuron 24:941-951
142. Kisanuki YY, Chemelli RM, Sinton CM, Williams SC, Richardson JA, Hammer RE, and Yanagisawa M (2000) The role of orexin receptor type-1 (OX1R) in the regulation of sleep (Abstract). Sleep 23:A91
143. Klein DC, Moore RY, and Reppert SM (1991) Suprachiasmatic Nucleus: The Mind's Clock. Oxford University Press, New York, NY.
144. Kobashi M, Furudono Y, Matsuo R, and Yamamoto T (2002) Central orexin facilitates gastric relaxation and contractility in rats. Neurosci Lett 332:171-174
145. Kotz CM, Mullett MA, and Wang C (2005) Diminished feeding responsiveness to orexin A (hypocretin 1) in aged rats is accompanied by decreased neuronal activation. Am J Physiol Regul Integr Comp Physiol 289:R359-R366
146. Krowicki ZK, Burmeister MA, Berthoud HR, Scullion RT, Fuchs K, and Hornby PJ (2002) Orexins in rat dorsal motor nucleus of the vagus potently stimulate gastric motor function. Am J Physiol Gastrointest Liver Physiol 283:G465-G472
147. Kukkonen JP and Akerman KE (2001) Orexin receptors couple to Ca2+ channels different from store-operated Ca2+ channels. Neuroreport 12:2017-2020
148. Lancel M (1999) Role of GABAA receptors in the regulation of sleep: initial sleep responses to peripherally administered modulators and agonists. Sleep 22:33-42
149. Langmead CJ, Jerman JC, Brough SJ, Scott C, Porter RA, and Herdon HJ (2004) Characterisation of the binding of [3H]-SB-674042, a novel nonpeptide antagonist, to the human orexin-1 receptor. Br J Pharmacol 141:340-346
150. Larsson KP, Peltonen HM, Bart G, Louhivuori LM, Penttonen A, Antikainen M, Kukkonen JP, and Akerman KE (2005) Orexin-A-induced Ca2+ entry: evidence for involvement of trpc channels and protein kinase C regulation. J Biol Chem 280: 1771-1781
151. Lawrence AJ (2010) Regulation of alcohol-seeking by orexin (hypocretin) neurons. Brain Res 1314:124-129
152. Lectez B, Jeandel L, El-Yamani FZ, Arthaud S, Alexandre D, Mardargent A, Jégou S, Mounien L, Bizet P, Magoul R, et al. (2009) The orexigenic activity of the hypothalamic neuropeptide 26RFa is mediated by the neuropeptide Y and proopiomelanocortin neurons of the arcuate nucleus. Endocrinology 150:2342-2350
153. Lee J, Reddy MM, and Kodadek T (2010) Discovery of an orexin receptor positive potentiator. Chem Sci 1:48-54
154. Li A and Nattie E (2010) Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle. J Physiol 588:2935-2944
155. Li Y, Li S, Wei C, Wang H, Sui N, and Kirouac GJ (2010) Orexins in the paraventricular nucleus of the thalamus mediate anxiety-like responses in rats. Psychopharmacology 212:251-265
156. Li Y, Wang H, Qi K, Chen X, Li S, Sui N, and Kirouac GJ (2011) Orexins in the midline thalamus are involved in the expression of conditioned place aversion to morphine withdrawal. Physiol Behav 102:42-50
157. Lin J, Dauvilliers Y, Arnulf I, Anaclet C, Parmentier R, Ligneau X, Lecomte J, and Schwartz J (2008) An inverse agonist of the histamine H3-receptor improves wakefulness in narcolepsy: study in orexin-/- mice and patients (Abstract 0009). Sleep 31 (Suppl):A3
158. Lin JS, Sakai K, and Jouvet M (1988) Evidence for histaminergic arousal mechanisms in the hypothalamus of cat. Neuropharmacology 27:111-122
159. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, and Mignot E (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98:365-376
160. Liu J (2009), inventor. Tetrahydroisoquinoline derivatives. U.S. patent application no. 20090192188. 2009 Jul 30
161. Liu M, Blanco-Centurion C, Konadhode R, Begum S, Pelluru D, Gerashchenko D, Sakurai T, Yanagisawa M, van den Pol AN, and Shiromani PJ (2011) Orexin gene transfer into zona incerta neurons suppresses muscle paralysis in narcoleptic mice. J Neurosci 31:6028-6040
162. Liu RJ, van den Pol AN, and Aghajanian GK (2002) Hypocretins (orexins) regulate serotonin neurons in the dorsal raphe nucleus by excitatory direct and inhibitory indirect actions. J Neurosci 22:9453-9464
163. Louhivuori LM, Jansson L, Nordström T, Bart G, Näsman J, and Akerman KE (2010) Selective interference with TRPC3/6 channels disrupts OX1 receptor signalling via NCX and reveals a distinct calcium influx pathway. Cell Calcium 48:114-123
164. Louis GW, Leinninger GM, Rhodes CJ, and Myers MG Jr (2010) Direct innervation and modulation of orexin neurons by lateral hypothalamic LepRb neurons. J Neurosci 30:11278-11287
165. Lubkin M and Stricker-Krongrad A (1998) Independent feeding and metabolic actions of orexins in mice. Biochem Biophys Res Commun 253:241-245
166. Lund PE, Shariatmadari R, Uustare A, Detheux M, Parmentier M, Kukkonen JP, and Akerman KE (2000) The orexin OX1 receptor activates a novel Ca2+ influx pathway necessary for coupling to phospholipase C. J Biol Chem 275:30806-30812
167. Lutter M, Krishnan V, Russo SJ, Jung S, McClung CA, and Nestler EJ (2008) Orexin signaling mediates the antidepressant-like effect of calorie restriction. J Neurosci 28:3071-3075
168. Machado BH, Bonagamba LG, Dun SL, Kwok EH, and Dun NJ (2002) Pressor response to microinjection of orexin/hypocretin into rostral ventrolateral medulla of awake rats. Regul Pept 104:75-81
169. Malherbe P, Borroni E, Gobbi L, Knust H, Nettekoven M, Pinard E, Roche O, Rogers-Evans M, Wettstein JG, and Moreau JL (2009) Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor. Br J Pharmacol 156:1326-1341
170. Malherbe P, Roche O, Marcuz A, Kratzeisen C, Wettstein JG, and Bissantz C (2010) Mapping the binding pocket of dual antagonist almorexant to human orexin 1 and orexin 2 receptors: comparison with the selective OX1 antagonist SB-674042 and the selective OX2 antagonist N-ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]-N-pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol 78:81-93
171. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, and Elmquist JK (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 435:6-25
172. McAtee LC, Sutton SW, Rudolph DA, Li X, Aluisio LE, Phuong VK, Dvorak CA, Lovenberg TW, Carruthers NI, and Jones TK (2004) Novel substituted 4-phenyl-[1,3]dioxanes: potent and selective orexin receptor 2 (OX(2)R) antagonists. Bioorg Med Chem Lett 14:4225-4229
173. Mieda M, Willie JT, Hara J, Sinton CM, Sakurai T, and Yanagisawa M (2004) Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci USA 101:4649-4654
174. Miyasaka K, Masuda M, Kanai S, Sato N, Kurosawa M, and Funakoshi A (2002) Central Orexin-A stimulates pancreatic exocrine secretion via the vagus. Pancreas 25:400-404
175. Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Watanabe H, Kato M, Naghdi N, and Yanai K (2005a) Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. Pain 118:254-262
176. Mobarakeh JI, Takahashi K, Sakurada S, Nishino S, Watanabe H, Kato M, and Yanai K (2005b) Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and -2) in mice. Peptides 26:767-777
177. Mochizuki T, Arrigoni E, Marcus JN, Clark EL, Yamamoto M, Honer M, Borroni E, Lowell BB, Elmquist JK, and Scammell TE (2011) Orexin receptor 2 expression in the posterior hypothalamus rescues sleepiness in narcoleptic mice. Proc Natl Acad Sci USA 108:4471-4476
178. Mochizuki T, Crocker A, McCormack S, Yanagisawa M, Sakurai T, and Scammell TE (2004) Behavioral state instability in orexin knock-out mice. J Neurosci 24:6291-6300
179. Mochizuki T and Scammell TE (2003) Orexin/hypocretin: wired for wakefulness. Curr Biol 13:R563-R564
180. Monti JM, Pellejero T, and Jantos H (1986) Effects of H1-and H2-histamine receptor agonists and antagonists on sleep and wakefulness in the rat. J Neural Transm 66:1-11
181. Morawska M, Buchi M, and Fendt M (2011) Narcoleptic episodes in orexin-deficient mice are increased by both attractive and aversive odors. Behav Brain Res 222: 397-400
182. Morganstern I, Chang GQ, Karatayev O, and Leibowitz SF (2010) Increased orexin and melanin-concentrating hormone expression in the perifornical lateral hypothalamus of rats prone to overconsuming a fat-rich diet. Pharmacol Biochem Behav 96:413-422
183. Moriya R, Sano H, Umeda T, Ito M, Takahashi Y, Matsuda M, Ishihara A, Kanatani A, and Iwaasa H (2006) RFamide peptide QRFP43 causes obesity with hyperphagia and reduced thermogenesis in mice. Endocrinology 147:2916-2922
184. Muroya S, Uramura K, Sakurai T, Takigawa M, and Yada T (2001) Lowering glucose concentrations increases cytosolic Ca2+ in orexin neurons of the rat lateral hypothalamus. Neurosci Lett 309:165-168
185. Nair SG, Golden SA, and Shaham Y (2008) Differential effects of the hypocretin 1 receptor antagonist SB 334867 on high-fat food self-administration and reinstatement of food seeking in rats. Br J Pharmacol 154:406-416
186. Nakabayashi M, Suzuki T, Takahashi K, Totsune K, Muramatsu Y, Kaneko C, Date F, Takeyama J, Darnel AD, Moriya T, et al. (2003) Orexin-A expression in human peripheral tissues. Mol Cell Endocrinol 205:43-50
187. Nakamura A, Zhang W, Yanagisawa M, Fukuda Y, and Kuwaki T (2007) Vigilance state-dependent attenuation of hypercapnic chemoreflex and exaggerated sleep apnea in orexin knockout mice. J Appl Physiol 102:241-248
188. Näslund E, Ehrström M, Ma J, Hellström PM, and Kirchgessner AL (2002) Localization and effects of orexin on fasting motility in the rat duodenum. Am J Physiol Gastrointest Liver Physiol 282:G470-G479
189. Näsman J, Bart G, Larsson K, Louhivuori L, Peltonen H, and Akerman KE (2006) The orexin OX1 receptor regulates Ca2+ entry via diacylglycerol-activated channels in differentiated neuroblastoma cells. J Neurosci 26:10658-10666
190. Nattie E and Li A (2010) Central chemoreception in wakefulness and sleep: evidence for a distributed network and a role for orexin. J Appl Physiol 108:1417-1424
191. Niimi M, Sato M, and Taminato T (2001) Neuropeptide Y in central control of feeding and interactions with orexin and leptin. Endocrine 14:269-273
192. Nishino S (2005) The canine model of narcolepsy, in Hypocretins: Integrators of Physiological Functions (de Lecea L and Sutcliffe G eds) p. 39, Springer, New York.
193. Nishino S and Mignot E (1997) Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52:27-78
194. Nishino S, Okuro M, Kotorii N, Anegawa E, Ishimaru Y, Matsumura M, and Kanbayashi T (2010) Hypocretin/orexin and narcolepsy: new basic and clinical insights. Acta Physiol (Oxf) 198:209-222
195. Nishino S, Ripley B, Overeem S, Lammers GJ, and Mignot E (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355:39-40
196. Nisoli E, Carruba MO, Valerio A, and Borsani G (1998) Hypocretins or hyporexins? Nat Med 4:645
197. Nutt DJ and Stahl SM (2010) Searching for perfect sleep: the continuing evolution of GABAA receptor modulators as hypnotics. J Psychopharmacol 24:1601-1612
198. Ohno K and Sakurai T (2008) Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 29:70-87
199. Okumura T and Takakusaki K (2008) Role of orexin in central regulation of gastrointestinal functions. J Gastroenterol 43:652-660
200. Olds J and Milner P (1954) Positive reinforcement produced by electrical stimulation of septal area and other regions of rat brain. J Comp Physiol 47:419-427
201. Orlando G, Brunetti L, Di Nisio C, Michelotto B, Recinella L, Ciabattoni G, and Vacca M (2001) Effects of cocaine-and amphetamine-regulated transcript peptide, leptin and orexins on hypothalamic serotonin release. Eur J Pharmacol 430:269-272
202. Ozcan M, Ayar A, Serhatlioglu I, Alcin E, Sahin Z, and Kelestimur H (2010) Orexins activates protein kinase C-mediated Ca2+ signaling in isolated rat primary sensory neurons. Physiol Res 59:255-262
203. Peng HY, Chang HM, Chang SY, Tung KC, Lee SD, Chou D, Lai CY, Chiu CH, Chen GD, and Lin TB (2008) Orexin-A modulates glutamatergic NMDA-dependent spinal reflex potentiation via inhibition of NR2B subunit. Am J Physiol Endocrinol Metab 295:E117-E129
204. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R, et al. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Med 6:991-997
205. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, and Kilduff TS (1998) Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 18:9996-10015
206. Pinessi L, Binello E, De Martino P, Gallone S, Gentile S, Rainero I, Rivoiro C, Rubino E, Savi L, Valfrè W, et al. (2007) The 1246G->A polymorphism of the HCRTR2 gene is not associated with migraine. Cephalalgia 27:945-949
207. Piper DC, Upton N, Smith MI, and Hunter AJ (2000) The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur J Neurosci 12:726-730
208. Ponz A, Khatami R, Poryazova R, Werth E, Boesiger P, Bassetti CL, and Schwartz S (2010) Abnormal activity in reward brain circuits in human narcolepsy with cataplexy. Ann Neurol 67:190-200
209. Porkka-Heiskanen T, Strecker RE, and McCarley RW (2000) Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience 99:507-517
210. Putula J, Turunen PM, Johansson L, Näsman J, Ra R, Korhonen L, and Kukkonen JP (2011) Orexin/hypocretin receptor chimaeras reveal structural features important for orexin peptide distinction. FEBS Lett 585:1368-1374
211. Rachalski A, Alexandre C, Bernard JF, Saurini F, Lesch KP, Hamon M, Adrien J, and Fabre V (2009) Altered sleep homeostasis after restraint stress in 5-HTT knock-out male mice: a role for hypocretins. J Neurosci 29:15575-15585
212. Rainero I, Gallone S, Valfrè W, Ferrero M, Angilella G, Rivoiro C, Rubino E, De Martino P, Savi L, Ferrone M, et al. (2004) A polymorphism of the hypocretin receptor 2 gene is associated with cluster headache. Neurology 63:1286-1288
213. Rainero I, Rubino E, Gallone S, Fenoglio P, Picci LR, Giobbe L, Ostacoli L, and Pinessi L (2011) Evidence for an association between migraine and the hypocretin receptor 1 gene. J Headache Pain 12:193-199
214. Rainero I, Rubino E, Valfrè W, Gallone S, De Martino P, Zampella E, and Pinessi L (2007) Association between the G1246A polymorphism of the hypocretin receptor 2 gene and cluster headache: a meta-analysis. J Headache Pain 8:152-156
215. Renger JJ, Dunn SL, Motzel SL, Johnson C, and Koblan KS (2004) Sub-chronic administration of zolpidem affects modifications to rat sleep architecture. Brain Res 1010:45-54
216. Renzulli C, Nash M, Wright M, Thomas S, Zamuner S, Pellegatti M, Bettica P, and Boyle G (2011) Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans. Drug Metab Dispos 39:215-227
217. Ripley B, Fujiki N, Okura M, Mignot E, and Nishino S (2001) Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 8:525-534
218. Rodgers RJ, Halford JC, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JR, and Blundell JE (2000) Dose-response effects of orexin-A on food intake and the behavioural satiety sequence in rats. Regul Pept 96:71-84
219. Rodgers RJ, Halford JC, Nunes de Souza RL, Canto de Souza AL, Piper DC, Arch JR, Upton N, Porter RA, Johns A, and Blundell JE (2001) SB-334867, a selective orexin-1 receptor antagonist, enhances behavioural satiety and blocks the hyperphagic effect of orexin-A in rats. Eur J Neurosci 13:1444-1452
220. Rodgers RJ, Ishii Y, Halford JC, and Blundell JE (2002) Orexins and appetite regulation. Neuropeptides 36:303-325
221. Rolls A, Schaich Borg J, and de Lecea L (2010) Sleep and metabolism: role of hypothalamic neuronal circuitry. Best Pract Res Clin Endocrinol Metab 24:817-828
222. Rosenbaum DM, Cherezov V, Hanson MA, Rasmussen SG, Thian FS, Kobilka TS, Choi HJ, Yao XJ, Weis WI, Stevens RC, et al. (2007) GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 318:1266-1273
223. Sakurai T (2002) Roles of orexins in the regulation of feeding and arousal. Sleep Med 3 (Suppl 2):S3-S9
224. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92:573-585
225. Sakurai T and Mieda M (2011) Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol Sci 32:451-462
226. Sakurai T, Mieda M and Masashi Y (2005a) Rodent models of human narcolepsycataplexy, in Hypocretins: Integrators of Physiological Functions (de Lecea L and Sutcliffe G eds) p. 27, Springer, New York.
227. Sakurai T, Mieda M, and Tsujino N (2010) The orexin system: roles in sleep/wake regulation. Ann NY Acad Sci 1200:149-161
228. Sakurai T, Moriguchi T, Furuya K, Kajiwara N, Nakamura T, Yanagisawa M, and Goto K (1999) Structure and function of human prepro-orexin gene. J Biol Chem 274:17771-17776
229. Sakurai T, Nagata R, Yamanaka A, Kawamura H, Tsujino N, Muraki Y, Kageyama H, Kunita S, Takahashi S, Goto K, et al. (2005b) Input of orexin/hypocretin neurons revealed by a genetically encoded tracer in mice. Neuron 46:297-308
230. Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, and Mignot E (2003) Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry 54:96-104
231. Samson WK, Bagley SL, Ferguson AV, and White MM (2007) Hypocretin/orexin type 1 receptor in brain: role in cardiovascular control and the neuroendocrine response to immobilization stress. Am J Physiol Regul Integr Comp Physiol 292:R382-R387
232. Samson WK, Gosnell B, Chang JK, Resch ZT, and Murphy TC (1999) Cardiovascular regulatory actions of the hypocretins in brain. Brain Res 831:248-253
233. Saper CB, Fuller PM, Pedersen NP, Lu J, and Scammell TE (2010) Sleep state switching. Neuron 68:1023-1042
234. Saper CB, Lu J, Chou TC, and Gooley J (2005a) The hypothalamic integrator for circadian rhythms. Trends Neurosci 28:152-157
235. Saper CB, Scammell TE, and Lu J (2005b) Hypothalamic regulation of sleep and circadian rhythms. Nature 437:1257-1263
236. Sarchielli P, Rainero I, Coppola F, Rossi C, Mancini M, Pinessi L, and Calabresi P (2008) Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia 28:714-722
237. Sato-Suzuki I, Kita I, Seki Y, Oguri M, and Arita H (2002) Cortical arousal induced by microinjection of orexins into the paraventricular nucleus of the rat. Behav Brain Res 128:169-177
238. Satoh S, Matsumura H, Kanbayashi T, Yoshida Y, Urakami T, Nakajima T, Kimura N, Nishino S, and Yoneda H (2006) Expression pattern of FOS in orexin neurons during sleep induced by an adenosine A(2A) receptor agonist. Behav Brain Res 170:277-286
239. Scammell TE, Willie JT, Guilleminault C, Siegel JM, and International Working Group on Rodent Models of Narcolepsy (2009) A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 32:111-116
240. Scammell TE and Winrow CJ (2011) Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol 51:243-266
241. Schmidt FM, Brügel M, Kratzsch J, Strauss M, Sander C, Baum P, Thiery J, Hegerl U, and Schönknecht P (2010) Cerebrospinal fluid hypocretin-1 (orexin A) levels in mania compared to unipolar depression and healthy controls. Neurosci Lett 483: 20-22
242. Schuld A, Blum WF, and Pollmächer T (2002) Low cerebrospinal fluid hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 51: 660-661
243. Schuld A, Hebebrand J, Geller F, and Pollmacher T (2000) Increased body-mass index in patients with narcolepsy. Lancet 355:1274-1275
244. Schürks M, Kurth T, Geissler I, Tessmann G, Diener HC, and Rosskopf D (2006) Cluster headache is associated with the G1246A polymorphism in the hypocretin receptor 2 gene. Neurology 66:1917-1919
245. Schürks M, Kurth T, Geissler I, Tessmann G, Diener HC, and Rosskopf D (2007a) The G1246A polymorphism in the hypocretin receptor 2 gene is not associated with treatment response in cluster headache. Cephalalgia 27:363-367
246. Schürks M, Limmroth V, Geissler I, Tessmann G, Savidou I, Engelbergs J, Kurth T, Diener HC, and Rosskopf D (2007b) Association between migraine and the G1246A polymorphism in the hypocretin receptor 2 gene. Headache 47:1195-1199
247. Schwimmer H, Stauss HM, Abboud F, Nishino S, Mignot E, and Zeitzer JM (2010) Effects of sleep on the cardiovascular and thermoregulatory systems: a possible role for hypocretins. J Appl Physiol 109:1053-1063
248. Schwimmer H, Zeitzer JM, Masashi Y, Nishino S, Shengwen Z, and Mignot E (2006) Hypocretin/orexin effects on cardiovascular regulation during sleep (Abstract 0094). Sleep 29:A31
249. Scott MM, Marcus JN, Pettersen A, Birnbaum SG, Mochizuki T, Scammell TE, Nestler EJ, Elmquist JK, and Lutter M (2011) Hcrtr1 and 2 signaling differentially regulates depression-like behaviors. Behav Brain Res 222:289-294
250. Shahid IZ, Rahman AA, and Pilowsky PM (2011) Intrathecal orexin A increases sympathetic outflow and respiratory drive, enhances baroreflex sensitivity and blocks the somato-sympathetic reflex. Br J Pharmacol 162:961-973
251. Sharf R, Sarhan M, and Dileone RJ (2010) Role of orexin/hypocretin in dependence and addiction. Brain Res 1314:130-138
252. Shirasaka T, Nakazato M, Matsukura S, Takasaki M, and Kannan H (1999) Sympathetic and cardiovascular actions of orexins in conscious rats. Am J Physiol 277:R1780-R1785
253. Shoblock JR, Welty N, Aluisio L, Fraser I, Motley ST, Morton K, Palmer J, Bonaventure P, Carruthers NI, Lovenberg TW, et al. (2011) Selective blockade of the orexin-2 receptor attenuates ethanol self-administration, place preference, and reinstatement. Psychopharmacology 215:191-203
254. Siegel JM and Boehmer LN (2006) Narcolepsy and the hypocretin system-where motion meets emotion. Nat Clin Pract Neurol 2:548-556
255. Singareddy R, Uhde T, and Commissaris R (2006) Differential effects of hypocretins on noise-alone versus potentiated startle responses. Physiol Behav 89:650-655
256. Smart D, Jerman JC, Brough SJ, Neville WA, Jewitt F, and Porter RA (2000) The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors. Br J Pharmacol 129:1289-1291
257. Smart D, Jerman JC, Brough SJ, Rushton SL, Murdock PR, Jewitt F, Elshourbagy NA, Ellis CE, Middlemiss DN, and Brown F (1999) Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR. Br J Pharmacol 128:1-3
258. Smart D, Sabido-David C, Brough SJ, Jewitt F, Johns A, Porter RA, and Jerman JC (2001) SB-334867-A: the first selective orexin-1 receptor antagonist. Br J Pharmacol 132:1179-1182
259. Smith PM, Connolly BC, and Ferguson AV (2002) Microinjection of orexin into the rat nucleus tractus solitarius causes increases in blood pressure. Brain Res 950: 261-267
260. Smith PM, Samson WK, and Ferguson AV (2007) Cardiovascular actions of orexin-A in the rat subfornical organ. J Neuroendocrinol 19:7-13
261. Sonka K, Kemlink D, Busková J, Pretl M, Srůtková Z, Maurovich Horvat E, Vodicka P, Poláková V, and Nevsímalová S (2010) Obesity accompanies narcolepsy with cataplexy but not narcolepsy without cataplexy. Neuro Endocrinol Lett 31:631-634
262. Steiner MA, Lecourt H, Strasser DS, Brisbare-Roch C, and Jenck F (2011) Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-alpha1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat. Neuropsychopharmacology 36:848-856
263. Strawn JR, Pyne-Geithman GJ, Ekhator NN, Horn PS, Uhde TW, Shutter LA, Baker DG, and Geracioti TD Jr (2010) Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology 35:1001-1007
264. Sullivan SS and Guilleminault C (2009) Emerging drugs for insomnia: new frontiers for old and novel targets. Expert Opin Emerg Drugs 14:411-422
265. Suzuki M, Beuckmann CT, Shikata K, Ogura H, and Sawai T (2005) Orexin-A (hypocretin-1) is possibly involved in generation of anxiety-like behavior. Brain Res 1044:116-121
266. Sweet DC, Levine AS, Billington CJ, and Kotz CM (1999) Feeding response to central orexins. Brain Res 821:535-538
267. Taheri S, Sunter D, Dakin C, Moyes S, Seal L, Gardiner J, Rossi M, Ghatei M, and Bloom S (2000) Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system. Neurosci Lett 279:109-112
268. Takahashi N, Okumura T, Yamada H, and Kohgo Y (1999) Stimulation of gastric acid secretion by centrally administered orexin-A in conscious rats. Biochem Biophys Res Commun 254:623-627
269. Takano S, Kanai S, Hosoya H, Ohta M, Uematsu H, and Miyasaka K (2004) Orexin-A does not stimulate food intake in old rats. Am J Physiol Gastrointest Liver Physiol 287:G1182-G1187
270. Takayasu S, Sakurai T, Iwasaki S, Teranishi H, Yamanaka A, Williams SC, Iguchi H, Kawasawa YI, Ikeda Y, Sakakibara I, et al. (2006) A neuropeptide ligand of the G protein-coupled receptor GPR103 regulates feeding, behavioral arousal, and blood pressure in mice. Proc Natl Acad Sci USA 103:7438-7443
271. Tan KR, Rudolph U, and Lüscher C (2011) Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci 34:188-197
272. Thakkar MM, Engemann SC, Walsh KM, and Sahota PK (2008) Adenosine and the homeostatic control of sleep: effects of A1 receptor blockade in the perifornical lateral hypothalamus on sleep-wakefulness. Neuroscience 153:875-880
273. Thankachan S, Kaur S, and Shiromani PJ (2009) Activity of pontine neurons during sleep and cataplexy in hypocretin knock-out mice. J Neurosci 29:1580-1585
274. Thannickal TC, Siegel JM, Nienhuis R, and Moore RY (2003) Pattern of hypocretin (orexin) soma and axon loss, and gliosis, in human narcolepsy. Brain Pathol 13:340-351
275. Thorpe AJ, Doane DF, Sweet DC, Beverly JL, and Kotz CM (2006) Orexin A in the rostrolateral hypothalamic area induces feeding by modulating GABAergic transmission. Brain Res 1125:60-66
276. Thorpe AJ and Kotz CM (2005) Orexin A in the nucleus accumbens stimulates feeding and locomotor activity. Brain Res 1050:156-162
277. Thorpe AJ, Teske JA, and Kotz CM (2005) Orexin A-induced feeding is augmented by caloric challenge. Am J Physiol Regul Integr Comp Physiol 289:R367-R372
278. Thuau R, Guilhaudis L, Ségalas-Milazzo I, Chartrel N, Oulyadi H, Boivin S, Fournier A, Leprince J, Davoust D, and Vaudry H (2005) Structural studies on 26RFa, a novel human RFamide-related peptide with orexigenic activity. Peptides 26:779-789
279. Tran DT, Bonaventure P, Hack M, Mirzadegan T, Dvorak C, Letavic M, Carruthers N, Lovenberg T, and Sutton SW (2011) Chimeric, mutant orexin receptors show key interactions between orexin receptors, peptides and antagonists. Eur J Pharmacol 667:120-128
280. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, and Guan XM (1998) Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 438:71-75
281. Tsujino N and Sakurai T (2009) Orexin/hypocretin: a neuropeptide at the interface of sleep, energy homeostasis, and reward system. Pharmacol Rev 61:162-176
282. Tsuneki H, Wada T, and Sasaoka T (2010) Role of orexin in the regulation of glucose homeostasis. Acta Physiol (Oxf) 198:335-348
283. Uramura K, Funahashi H, Muroya S, Shioda S, Takigawa M, and Yada T (2001) Orexin-a activates phospholipase C-and protein kinase C-mediated Ca2+ signaling in dopamine neurons of the ventral tegmental area. Neuroreport 12:1885-1889.
284. van den Pol AN (1999) Hypothalamic hypocretin (orexin): robust innervation of the spinal cord. J Neurosci 19:3171-3182.
285. van den Pol AN, Gao XB, Obrietan K, Kilduff TS, and Belousov AB (1998) Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin. J Neurosci 18:7962-7971
286. Van Den Pol AN, Patrylo PR, Ghosh PK, and Gao XB (2001) Lateral hypothalamus: early developmental expression and response to hypocretin (orexin). J Comp Neurol 433:349-363
287. Velley L, Chaminade C, Roy MT, Kempf E, and Cardo B (1983) Intrinsic neurons are involved in lateral hypothalamic self-stimulation. Brain Res 268:79-86
288. Voisin T, Rouet-Benzineb P, Reuter N, and Laburthe M (2003) Orexins and their receptors: structural aspects and role in peripheral tissues. Cell Mol Life Sci 60:72-87
289. Watanabe S, Kuwaki T, Yanagisawa M, Fukuda Y, and Shimoyama M (2005) Persistent pain and stress activate pain-inhibitory orexin pathways. Neuroreport 16:5-8
290. Welsh DK, Logothetis DE, Meister M, and Reppert SM (1995) Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms. Neuron 14:697-706
291. White MM, Bagley SL, and Samson WK (2006) Orexin/hypocretin receptor subtypes: cardiovascular and behavioral effects. FASEB J 20:A366
292. Williams KS and Behn CG (2011) Dynamic interactions between orexin and dynorphin may delay onset of functional orexin effects: a modeling study. J Biol Rhythms 26:171-181
293. Williams RH, Jensen LT, Verkhratsky A, Fugger L, and Burdakov D (2007) Control of hypothalamic orexin neurons by acid and CO2 Proc Natl Acad Sci USA 104: 10685-10690
294. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA, et al. (2003) Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38:715-730
295. Willie JT, Chemelli RM, Sinton CM, and Yanagisawa M (2001) To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 24:429-458
296. Winrow CJ, Gotter AL, Cox CD, Doran SM, Tannenbaum PL, Breslin MJ, Garson SL, Fox SV, Harrell CM, Stevens J, et al. (2011) Promotion of sleep by suvorexant-a novel dual orexin receptor antagonist. J Neurogenet 25:52-61
297. Winrow CJ, Gotter AL, Cox CD, Tannenbaum PL, Garson SL, Doran SM, Breslin MJ, Schreier JD, Fox SV, Harrell CM, et al. (2012) Pharmacological characterization of MK-6096-a dual orexin receptor antagonist for insomnia. Neuropharmacology 62:978-987
298. Wong KK, Ng SY, Lee LT, Ng HK, and Chow BK (2011) Orexins and their receptors from fish to mammals: a comparative approach. Gen Comp Endocrinol 171:124-130
299. Wortley KE, Chang GQ, Davydova Z, and Leibowitz SF (2003) Peptides that regulate food intake: orexin gene expression is increased during states of hypertriglyceridemia. Am J Physiol Regul Integr Comp Physiol 284:R1454-R1465
300. Wu MF, John J, Maidment N, Lam HA, and Siegel JM (2002) Hypocretin release in normal and narcoleptic dogs after food and sleep deprivation, eating, and movement. Am J Physiol Regul Integr Comp Physiol 283:R1079-R1086
301. Wu X, Gao J, Yan J, Owyang C, and Li Y (2004) Hypothalamus-brain stem circuitry responsible for vagal efferent signaling to the pancreas evoked by hypoglycemia in rat. J Neurophysiol 91:1734-1747
302. Xie X, Wisor JP, Hara J, Crowder TL, LeWinter R, Khroyan TV, Yamanaka A, Diano S, Horvath TL, Sakurai T, et al. (2008) Hypocretin/orexin and nociceptin/orphanin FQ coordinately regulate analgesia in a mouse model of stress-induced analgesia. J Clin Invest 118:2471-2481
303. Yamada H, Okumura T, Motomura W, Kobayashi Y, and Kohgo Y (2000) Inhibition of food intake by central injection of anti-orexin antibody in fasted rats. Biochem Biophys Res Commun 267:527-531
304. Yamada H, Takahashi N, Tanno S, Nagamine M, Takakusaki K, and Okumura T (2005) A selective orexin-1 receptor antagonist, SB334867, blocks 2-DG-induced gastric acid secretion in rats. Neurosci Lett 376:137-142
305. Yamamoto T, Miyazaki R, and Yamada T (2009) Intracerebroventricular administration of 26RFa produces an analgesic effect in the rat formalin test. Peptides 30:1683-1688
306. Yamamoto T, Nozaki-Taguchi N, and Chiba T (2002) Analgesic effect of intrathecally administered orexin-A in the rat formalin test in the rat hot plate test. Br J Pharmacol 137:170-176
307. Yamamoto T, Saito O, Shono K, Aoe T, and Chiba T (2003a) Anti-mechanical allodynic effect of intrathecal and intracerebroventricular injection of orexin-A in the rat neuropathic pain model. Neurosci Lett 347:183-186
308. Yamamoto T, Saito O, Shono K, and Hirasawa S (2003b) Activation of spinal orexin-1 receptor produces anti-allodynic effect in the rat carrageenan test. Eur J Pharmacol 481:175-180
309. Yamamoto T, Wada T, and Miyazaki R (2008) Analgesic effects of intrathecally administered 26RFa, an intrinsic agonist for GPR103, on formalin test and carrageenan test in rats. Neuroscience 157:214-222
310. Yamanaka A, Beuckmann CT, Willie JT, Hara J, Tsujino N, Mieda M, Tominaga M, Yagami K, Sugiyama F, Goto K, et al. (2003) Hypothalamic orexin neurons regulate arousal according to energy balance in mice. Neuron 38:701-713
311. Yamanaka A, Tsujino N, Funahashi H, Honda K, Guan JL, Wang QP, Tominaga M, Goto K, Shioda S, and Sakurai T (2002) Orexins activate histaminergic neurons via the orexin 2 receptor. Biochem Biophys Res Commun 290:1237-1245
312. Yan JA, Ge L, Huang W, Song B, Chen XW, and Yu ZP (2008) Orexin affects dorsal root ganglion neurons: a mechanism for regulating the spinal nociceptive processing. Physiol Res 57:797-800
313. Yanagisawa M (2010) Small-molecule agonists for type-2 orexin receptor. U.S. Patent application no. 20100150840. 2010 Jun 17
314. Yi CX, Serlie MJ, Ackermans MT, Foppen E, Buijs RM, Sauerwein HP, Fliers E, and Kalsbeek A (2009) A major role for perifornical orexin neurons in the control of glucose metabolism in rats. Diabetes 58:1998-2005
315. Yoshida K, McCormack S, España RA, Crocker A, and Scammell TE (2006) Afferents to the orexin neurons of the rat brain. J Comp Neurol 494:845-861
316. Zeitzer JM, Buckmaster CL, Parker KJ, Hauck CM, Lyons DM, and Mignot E (2003) Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J Neurosci 23:3555-3560
317. Zhang S, Lin L, Kaur S, Thankachan S, Blanco-Centurion C, Yanagisawa M, Mignot E, and Shiromani PJ (2007) The development of hypocretin (orexin) deficiency in hypocretin/ataxin-3 transgenic rats. Neuroscience 148:34-43
318. Zhang W, Fukuda Y, and Kuwaki T (2005) Respiratory and cardiovascular actions of orexin-A in mice. Neurosci Lett 385:131-136
319. Zhang W, Sakurai T, Fukuda Y, and Kuwaki T (2006) Orexin neuron-mediated skeletal muscle vasodilation and shift of baroreflex during defense response in mice. Am J Physiol Regul Integr Comp Physiol 290:R1654-R1663
320. Zhou L, Wei-Lun S, and See RE (2011) Orexin receptor targets for anti-relapse medication development in drug addiction. Pharmaceuticals 4:804-821
321. Zhu Y, Miwa Y, Yamanaka A, Yada T, Shibahara M, Abe Y, Sakurai T, and Goto K (2003) Orexin receptor type-1 couples exclusively to pertussis toxin-insensitive G-proteins, while orexin receptor type-2 couples to both pertussis toxin-sensitive and -insensitive G-proteins. J Pharmacol Sci 92:259-266.